| Quantifying the burden of informal caregiving for patients with cancer in Europe A Goren, I Gilloteau, M Lees, M daCosta DiBonaventura Supportive Care in Cancer 22, 1637-1646, 2014 | 184 | 2014 |
| Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study GV Long, V Atkinson, PA Ascierto, C Robert, JC Hassel, P Rutkowski, ... Annals of Oncology 27 (10), 1940-1946, 2016 | 132 | 2016 |
| Sleep problems in patients with rheumatoid arthritis R Westhovens, K Van der Elst, A Matthys, M Tran, I Gilloteau The Journal of rheumatology 41 (1), 31-40, 2014 | 127 | 2014 |
| Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges L Noens, M Hensen, I Kucmin-Bemelmans, C Lofgren, I Gilloteau, ... Haematologica 99 (3), 437, 2014 | 95 | 2014 |
| A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey CEM Griffiths, SJ Jo, L Naldi, R Romiti, E Guevara‐Sangines, T Howe, ... British journal of dermatology 179 (1), 173-181, 2018 | 94 | 2018 |
| Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results) J Bagel, J Nia, PW Hashim, M Patekar, A de Vera, S Hugot, K Sheng, ... Dermatology and Therapy 8, 571-579, 2018 | 78 | 2018 |
| Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study R Bissonnette, T Luger, D Thaçi, D Toth, I Messina, R You, A Guana, ... British Journal of Dermatology 177 (4), 1033-1042, 2017 | 73 | 2017 |
| Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response … BE Elewski, L Puig, M Mordin, I Gilloteau, B Sherif, T Fox, A Gnanasakthy, ... Journal of dermatological treatment 28 (6), 492-499, 2017 | 61 | 2017 |
| Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective US database SR Feldman, H Tian, I Gilloteau, P Mollon, M Shu BMC health services research 17, 1-8, 2017 | 60 | 2017 |
| Псориаз: клинико-эпидемиологические АЛ Бакулев, ТВ Фитилева, ЕА Новодережкина, И Гиллотю, Х Тиан, ... Vestnik Dermatologii i Venerologii 94 (3), 67-76, 2018 | 46* | 2018 |
| Caring for relatives with lung cancer in Europe: an evaluation of caregivers’ experience J Jassem, JR Penrod, A Goren, I Gilloteau Quality of Life Research 24, 2843-2852, 2015 | 42 | 2015 |
| Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate‐to‐severe psoriasis in five European countries M Augustin, J Vietri, H Tian, I Gilloteau Journal of the European Academy of Dermatology and Venereology 31 (8), 1316-1323, 2017 | 36 | 2017 |
| Patient-reported outcomes are important elements of psoriasis treatment decision making: a discrete choice experiment survey of dermatologists in the United States SR Feldman, SA Regnier, A Chirilov, F Hey, I Gilloteau, D Cella Journal of the American Academy of Dermatology 80 (6), 1650-1657, 2019 | 34 | 2019 |
| Patient–dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real‐world multinational survey CEM Griffiths, M Augustin, L Naldi, R Romiti, E Guevara‐Sangines, ... Journal of the European Academy of Dermatology and Venereology 32 (9), 1523-1529, 2018 | 33 | 2018 |
| Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study L Puig, M Augustin, A Blauvelt, AB Gottlieb, R Vender, NJ Korman, ... Journal of the American Academy of Dermatology 78 (4), 741-748, 2018 | 32 | 2018 |
| Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany M Augustin, D McBride, I Gilloteau, C O'neill, K Neidhardt, CN Graham Journal of the European Academy of Dermatology and Venereology 32 (12), 2191 …, 2018 | 30 | 2018 |
| Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with … LMG Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T ... J Am Acad Dermatol. 76 (4), 655-661, 2017 | 28 | 2017 |
| Disease burden and treatment patterns of psoriasis in Russia: a real-world patient and dermatologist survey AA Kubanov, AL Bakulev, TV Fitileva, E Novoderezhkina, I Gilloteau, ... Dermatology and therapy 8, 581-592, 2018 | 23 | 2018 |
| Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR study SR Feldman, Y Zhao, I Gilloteau, CN Graham, LS Miles, D McBride, ... Journal of Managed Care & Specialty Pharmacy 24 (7), 617-622, 2018 | 22 | 2018 |
| Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52 … TS Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao ... J Eur Acad Dermatol Venereol. 31 (10), 1692-1699, 2017 | 21* | 2017 |
